Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5

Rhea-AI Summary

Calidi Biotherapeutics (NYSE American: CLDI) has announced an upcoming live investor webinar scheduled for February 5, 2025, at 4:15 p.m. ET. The event will feature presentations from CFO Andrew Jackson and CSO Antonio F. Santidrian, who will discuss the company's cell-based delivery platforms for enhanced cancer treatment.

The webinar will showcase Calidi's leading programs, including CLD-400 for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade glioma. The event, hosted by RedChip Companies, will include a live Q&A session with management. Investors can register for free and submit questions in advance or during the event.

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, who will share insight into the company’s groundbreaking cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Highlights will include overviews of Calidi’s lead programs, such as its CLD-400 systemic platform targeting metastatic cancers, CLD-201 for advanced solid tumors and CLD-101 for high-grade glioma. A live Q&A session with the leadership team will follow the presentation.

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_qCp0OhjDSSaqiz3QsW9C_A#/registration

Questions can be pre-submitted to CLDI@redchip.com or online during the live event.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company’s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time.

Corporate Communications:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com   

Source: Calidi Biotherapeutics, Inc.

FAQ

When is Calidi Biotherapeutics (CLDI) hosting its investor webinar?

Calidi Biotherapeutics is hosting its investor webinar on February 5, 2025, at 4:15 p.m. ET.

What cancer treatment programs will be discussed during CLDI's February 2025 webinar?

The webinar will discuss CLD-400 for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade glioma.

Who are the key speakers at CLDI's February 2025 investor webinar?

CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, will be the key speakers at the webinar.

How can investors participate in CLDI's February 2025 webinar?

Investors can register for free through the RedChip webinar link and can submit questions either in advance to CLDI@redchip.com or during the live event.